Background Substantial evidence links exposure to moderate or high doses of ionising radiation,
for chronic myeloid leukaemia (p=0·394). There were few indications of between-cohort heterogeneity or departure from linearity. For acute myeloid leukaemia and myelodysplastic syndromes and for acute lymphoblastic leukaemia, the dose-responses remained significant for doses of less than 50 mSv. Excess absolute risks at 100 mSv were in the range of 0·1-0·4 cases or deaths per 10 000 person-years.
Interpretation
The risks of acute myeloid leukaemia and acute lymphoblastic leukaemia were significantly increased after cumulative doses of ionising radiation of less than 100 mSv in childhood or adolescence, with an excess risk also apparent for radiation doses of less than 50 mSv for some endpoints. These findings support an increased risk of leukaemia associated with lowdose exposure to radiation and imply that the current system of radiological protection is prudent and not overly protective.
Funding National Cancer Institute Intramural Research Program and National Cancer
Institute/NIH awards R03CA188614+R01CA197422.
INTRODUCTION
Leukaemia is the main sentinel radiogenic malignancy; the red (active) bone marrow is among the most radiosensitive of any organ or tissue, and leukaemia generally appears sooner than any other cancer after exposure to ionising radiation 1 . At moderate-to-high doses (>0.5 Sv) there is abundant evidence of radiation-related excess risk for most major leukaemia subtypes, in particular acute myeloid leukaemia, and chronic myeloid leukaemia, and to a lesser extent acute lymphoblastic leukaemia 1 . There is little evidence of an association with chronic lymphocytic leukaemia 1 , now classified as a non-Hodgkin lymphoma 2 . There is emerging evidence of radiogenic risk associated with myelodysplastic syndromes, a myeloid-lineage precursor to acute myeloid leukaemia 3 .
Particularly high excess relative risks of subsequent leukaemia have been reported following radiation exposure in childhood 1 . Evidence of risk at lower doses is less well established, in particular at radiation doses to the active bone marrow (ABM) of 100 mSv or less (the level of dose often used to demarcate low dose 1,4 ), with some claiming a threshold for leukaemia and other cancers, below which there is no excess cancer risk 5 . Most population exposures are from natural background radiation, diagnostic medical tests, or occupational, and are typically low doses 6 , so evaluating risks in this dose range is critical for radiation-protection purposes.
Because radiation exposure in childhood has been shown to confer the highest proportionally increased risks for subsequent leukaemia 1 , which are also higher than for any other malignancy, individuals with childhood exposures afford the best opportunity for studying low-dose cancer risks. Leukaemias are a rare cancer type and most individual studies do not have sufficient numbers of cases that have received low-dose ionising radiation exposure to provide adequate statistical power to estimate risk accurately. To directly evaluate low dose leukaemia risk, we have therefore conducted a pooled analysis of eligible cohorts that have received radiation exposure at a young age to assess risks of leukaemia following low-dose (<100 mSv) exposure to external sources of (predominantly photon) radiation, generally for medical diagnosis or treatment of benign conditions; lymphomas and multiple myeloma were not included because of evidence that these diseases have limited sensitivity to induction by radiation 1 . We excluded any groups treated for malignant conditions, in which chemotherapy would potentially be a strong confounder. Particular emphasis was placed on known radiogenic leukaemia subtypes, specifically (a) acute myeloid leukaemia with/without myelodysplastic syndromes, (b) chronic myeloid leukaemia, (c) acute lymphoblastic leukaemia. We also evaluated acute leukaemia and all leukaemia excluding chronic lymphocytic leukaemia for comparison with groupings used in earlier studies, and to include leukaemias (excluding chronic lymphocytic leukaemia) that are otherwise unspecified. The primary hypothesis was that radiation would increase risk of all radiogenic leukaemia even at low doses.
METHODS

Study design and participants
Overall study design
We examined all available cohort studies reporting on or before 30 th June 2014, with ≥5 leukaemias or other myeloid malignancies receiving mean cumulative radiation doses to the ABM >0.005 Sv among people first exposed while aged <21 years. Particularly when subtype-specific analyses are performed, cohorts that include <5 malignancies would almost certainly be uninformative in cohort-stratified analyses. We excluded any studies of patients being treated for malignant disease, in which chemotherapy would potentially be a strong confounder. We required that the cohorts include cumulative ABM dose estimates for each individual, and we reviewed the quality and completeness of the dosimetry, as outlined in Web-appendix pp. 5-7. We identified eligible cohorts from the most recent comprehensive summaries by international committees 1 combined with recent literature reviews 7 and PubMed literature searches (using the terms "leukaemia" + "radiation" + "medical" + "diagnosis", "leukaemia" + "radiation" + "medical" + "therapy"). The searches were conducted on a number of dates, and in final form on 29 th May 2018. The following ten cohorts met the eligibility criteria: the paediatrically-exposed (age at treatment <21 years) patients of the Massachusetts tuberculosis (TB) fluoroscopy cohort 8 ; the paediatrically-exposed (age at treatment <21 years) patients of the Canadian TB fluoroscopy cohort 9 ; the French haemangioma cohort 10 ; the Göteborg haemangioma cohort 11 ; the Stockholm haemangioma cohort 12 ; the Israeli tinea capitis cohort 13 ; the paediatrically-exposed (age at exposure <20 years) subjects of the Japanese atomic bomb survivor Life Span Study (LSS) cohort 14 ; the Rochester thymus enlargement cohort 15 ; the US scoliosis cohort 16 ; and the UK-National
Cancer Institute (NCI) computerised tomography (CT) cohort 3 . Cohorts excluded were those in which subjects mostly received radiation exposures from internally deposited radionuclides, dosimetry was inadequately described, and those with <5 leukaemia/myeloid malignancies.
Studies that employed a case-control design were also excluded, because of the need to fit generalised additive models (GAM, see below) 17 . Apart from the LSS cohort, the datasets comprised medically-exposed groups (diagnostic and therapeutic). Analysis was restricted to all members of these cohorts with mean cumulative ABM doses <100 mSv; as the Israeli tinea capitis cohort did not have any patients exposed to ABM doses <100 mSv, it was excluded from the present low-dose analysis but has been included in an ongoing study of these cohorts using unrestricted doses.
Follow-up started generally at the end of diagnosis/treatment for medically-irradiated groups, and continued until the earliest of date of cancer diagnosis, date of death, loss to followup or the end of the study; however, for the Massachusetts TB fluoroscopy cohort, follow-up began at the date of admission to one of the participating TB treatment institutions. Loss to follow-up is a particular concern for the Massachusetts TB fluoroscopy cohort, the scoliosis cohort and the French haemangioma cohort; it was dealt with, as in all other cohorts, by censoring at date of last known vital status. Person-years of follow-up in the LSS were adjusted to account for likely inand out-migration from the two cities of the relevant at-risk cohort, using similar survey-derived migration rate data as that used in the recent analysis of Hsu et al 14 .
The plausible assumption was made in all cohorts that such censoring was non-informative with respect to the endpoints being considered. Follow-up in some groups (Canadian TB fluoroscopy cohort, Rochester thymus enlargement cohort, Swedish haemangioma cohorts, LSS cohort) began either on the date of establishment of the relevant mortality registers (Canadian TB fluoroscopy study -1 January 1950,
Rochester thymus enlargement cohort -1 January 1979), or national cancer registries (Swedish haemangioma cohorts -1 January 1958), or the Japanese national census establishing the LSS cohort (1 October 1950). Follow-up in the UK-NCI CT study started at the date of the first CT.
More detailed information on dates of entry are given in Web-appendix p. 12.
Further details of the study cohorts are given in Web-appendix pp. 2-3, and of follow-up in the individual cohorts in Web-appendix p. 4. The protocol was finalised on 21 st March 2016.
Randomization and masking
All data received by the statistical analyst (MPL) was in fully anonymised form.
Procedures
Radiation dosimetry
Cumulative doses averaged over the whole-body ABM were calculated for each subject in the cohorts according to methods described previously. A variety of different methods were used in the component cohorts, but most other than the LSS were based on medical record abstraction of the original treatments (including descriptions of treatments received) and relevant patient data.
For the Massachusetts TB, Canadian TB, LSS, US spinal curvature, and UK-NCI CT cohorts Monte Carlo simulated dosimetry was used, while for all other cohorts a methodology based on physical measurements was used to estimate doses. The LSS dosimetry was particularly complex, accounting for both the source terms, radiation transport through air, shielding by terrain and physical structures and by the body itself 18 . Doses were expressed as equivalent doses in Sv.
Further details are given in Web-appendix pp. 5-7. The pooled analysis generally used the most recently calculated set of doses described in these studies, specifically the DS02R1 with corrections to Hiroshima and Nagasaki map coordinates and terrain shielding, as employed in the latest analysis of the LSS cancer incidence data 14 .
Outcomes
Identification and classification
The methods/sources of case identification were study-specific. These included: (1) The groups of malignancies considered in this study were those for which there was previous evidence of radiogenicity 1 
Statistical analysis
The key covariates evaluated in individual cohorts and in the pooled analysis were selected because they are known to modify leukaemia risk or were potentially important effect modifiers 1 and were available from all of the cohorts. The covariates included sex, age at entry, age first exposed to radiation, age last exposed, age attained, year of birth, years since first exposure, years since last exposure, and two-year lagged mean ABM dose accumulated in moving windows by time since exposure/age at exposure.
The primary hypothesis was that radiation would increase risk of all radiogenic leukaemia even at low doses. Accordingly, the primary model used for reporting results was the linear relative risk (RR) model, a model that has been found to fit radio-epidemiological data well at low doses 1 . We estimated the RR at 100 mSv of mean cumulative ABM dose (RR/100 mSv) for each outcome via the fit of the continuous dose-response model, and also assessed the RR for predefined dose-categories using the unexposed group (0 mSv) as the reference category. We compared the fit of linear and linear-exponential models in dose to determine whether there was possible non-linearity of RR with dose. We also assessed whether the risk varied with time since exposure or age at exposure. Mean cumulative ABM doses were lagged by 2 years, chosen a priori 1 , but a sensitivity analysis was conducted assessing lags of 0, 5 and 10 years. Although not used in the final analysis, the cohort was also stratified by certain other variables (years from first exposure, years from last exposure, age at entry, entry year, years from study entry); further details are given in Web-appendix p. 10. Likelihood-ratio tests of heterogeneity 20 across datasets were used, testing statistical compatibility of the RR at 100 mSv (which we shall write henceforth as RR/100 mSv) in each dataset against the common RR/100 mSv in the remaining eight cohorts, for each endpoint. GAMs were also fitted 17 , in order to assess the magnitude of the excess absolute risk (EAR), i.e. the radiation-associated extra cases/deaths per person and year of follow-up, for each outcome and cohort. Further statistical details are given in Web-appendix p. 28.
Role of the funding sources
The funding sources had no role in: study design; data collection, analysis, and interpretation of data; writing of the report; or the decision to submit the paper for publication. Only MPL, JSM and DC had access to the complete raw data. The corresponding author (MPL) had full access to all of the data and the final responsibility to submit for publication.
Ethical approval
The study cohort has been declared exempt by the National Cancer Institute Special Studies Institution Review Board, because using pre-existing approved data.
Contributors
MPL/ABdG/MSL conceived and designed the study, and produced an analytical plan. MPL was responsible for acquisition/processing of data and for analysis. DB/CL critically assessed the dosimetry. MPL/RW/ABdG/MSL interpreted the results. MPL produced a first draft of the manuscript. All authors reviewed the manuscript and provided intellectual input.
RESULTS
The combined nine cohorts included 262,573 persons in the studied dose range from 0 to 100 mSv, accumulating 5,154,464 person-years of follow-up (Table 1 Figure 1 . For no endpoint was there significant curvilinearity (p>0.15) (Web-appendix p. 13), nor was there for the medically-exposed groups of diagnostic and therapeutic studies considered separately (p>0.10) (results not shown). Table 2 ). There was no evidence of curvilinearity for either of these grouped endpoints, nor was there for the groups of diagnostic and therapeutic studies considered separately (p>0.5) (results not shown).
Accounting for dose in the period 2-5 years before the point of evaluation of risk significantly improved the model fit over that for dose received 5 years for acute myeloid leukaemia+myelodysplastic syndromes, acute lymphoblastic leukaemia, acute leukaemia and leukaemia excluding chronic lymphocytic leukaemia (all p<0.05), and resulted in marginally significant improvements in model fit (0.1>p>0.05) for all myeloid neoplasms and acute myeloid leukaemia (Web-appendix p. 19). There were indications (p≈0.05) that accounting for dose in the period 0-2 years before point of risk improved the model fit for all myeloid neoplasms, acute myeloid leukaemia+myelodysplastic syndromes and acute myeloid leukaemia (Web-appendix p.
19). In general, the effect of increasing the dose lag period was to decrease the RR and increase the associated p-value, but for acute lymphoblastic leukaemia increasing the lag from 0 year to 2 years resulted in a notably increased RR (relative to that using the 0 year lag) that became indications for most endpoints that risks were slightly higher in the diagnostic group than in the therapeutic group, and both tended to be higher than those in the LSS. In addition, although there were indications of higher risk for mortality compared with incidence for most malignant endpoints (with the exception of acute lymphoblastic leukaemia and leukaemia excluding chronic lymphocytic leukaemia), the differences were not statistically significant (p>0.10) (Web-appendix p. 24).
Excess absolute risks were generally small in our study: in the range 0.1-0.4 cases/deaths per 10,000 person-years at 100 mSv (Web-appendix p. 25); it should be noted that some of the models did not converge for the rarer endpoints.
We also analysed the magnitude of the variation of baseline absolute risk by cohort (using the LSS as the reference cohort) (Web-appendix p. 26); there was no significant variation between the cohort baseline risks for leukaemia excluding chronic lymphocytic leukaemia (p=0.52), although there were indications of differences for acute myeloid leukaemia (p=0.02) and acute myeloid leukaemia+myelodysplastic syndromes (p=0.03). There were consistent relative elevations in the baseline risks for the Göteborg haemangioma and US scoliosis cohorts for all three of these endpoints; otherwise, the variations were relatively modest. Although not shown in Web-appendix p. 26, because of non-convergence, there were only weak indications of heterogeneity of baseline risk by cohort for acute lymphoblastic leukaemia (p=0.31) and chronic myeloid leukaemia (p=0.07).
DISCUSSION
In this pooled analysis of leukaemia and myeloid malignancies in nine cohorts of those exposed in childhood or adolescence to ionising radiation with mean cumulative ABM doses <100 mSv we observed a significant linear dose-response for acute myeloid leukaemia (with or without myelodysplastic syndromes), acute lymphoblastic leukaemia and the grouped category of acute leukaemia. A cumulative ABM dose of 100 mSv in childhood/adolescence resulted in the risks of acute myeloid leukaemia (with or without myelodysplastic syndromes) and acute leukaemia increasing by factors of ~2.6 to 3.1, and the risk of acute lymphoblastic leukaemia increasing by a factor of ~5.7 (Table 2 ). For acute myeloid leukaemia+myelodysplastic syndromes, acute lymphoblastic leukaemia and acute leukaemia, risks were significantly elevated also at <50 mSv, and for acute lymphoblastic leukaemia at <20 mSv (Table 3) . Because these diseases are rare the excess absolute risks were small, in the range of 0.1-0.4 excess cases/deaths per 10,000 personyears at 100 mSv. There was no significant trend with dose for chronic myeloid leukaemia, which is known to be radiogenic 1 ; the relatively small number of such cases (36) and limited statistical power to assess risk at low doses may be a factor in the lack of significant trend of this endpoint here, due to the limited follow-up in these cohorts at the ages when chronic myeloid leukaemia would be most expected 1 .
Although there have been previous pooled analyses of radiation exposure and leukaemia risk (e.g., Little et al. 23 , Leuraud et al. 24 ) this study is, to the best of our knowledge, the first to estimate risks of leukaemia and myeloid neoplasms following exposures to low levels of radiation during childhood and adolescence. This is the exposure range that is relevant for most people as There have been a number of other studies of low dose-rates (but not necessarily low cumulative doses) of environmental radiation exposure of children and adults. Children exposed to low ABM doses as a result of the Chernobyl nuclear accident have been investigated 29 , and although some aspects of these studies (as highlighted by the authors) have been problematic, particularly the methods of control selection and the potential for recall bias, the leukaemia risks are compatible with those reported here (Web-appendix p. 27). The leukaemia RRs observed in residents near the contaminated Techa River in Russia (with 72 cases of leukaemia excluding chronic lymphocytic leukaemia among those exposed at all ages), in a small study of persons exposed to 60 Co-contaminated steel in apartment buildings in Taiwan (with 11 cases of leukaemia excluding chronic lymphocytic leukaemia among those exposed at all ages), and in another small study of residents of a high-natural background area in India (with 20 cases of leukaemia excluding chronic lymphocytic leukaemia among those exposed at all ages) are also consistent with the present findings (Web-appendix p. 27), although these studies generally have had limited power because the numbers of persons exposed at a young age have been relatively small 19 compared to our pooled analysis. In addition, there have been many studies examining effects of medical diagnostic exposures in the perinatal period in which doses were generally low (<0.1 Gy), but results have been difficult to interpret reliably 7, 30 , and in many instances these studies have lacked statistical power. However, studies of protracted low-dose, low-dose-rate radiation exposures of workersalthough not involving childhood/adolescent exposures -have also shown increased leukaemia risks, particularly chronic myeloid leukaemia 24, 31 (Web-appendix p. 27). In summary, in most of these other low-dose or low dose-rate studies there are indications of radiation-associated excess leukaemia risk, even where these are not conventionally statistically significant, with risk estimates that are compatible with our own.
To the best of our knowledge, all of the substantial cohort studies of leukaemia after lowdose exposure in childhood/adolescence that meet the eligibility criteria (see Web-appendix pp. 2-3 for details of the few excluded studies) have been included in this analysis. One limitation of this study is that the dosimetry was not uniform between the cohorts, as discussed in Web-appendix pp. 2-3, 5. Although the cohorts were exposed at low cumulative doses (<100 mSv) when averaged over all ABM compartments, consideration must be given to the heterogeneity in ABM dose (due to the specificity of the anatomic sites undergoing diagnostic examination or treatment) for all cohorts apart from the LSS. Therefore, a mean cumulative ABM dose of 100 mSv could potentially, in some of the therapeutically-exposed cohorts, e.g., the haemangioma cohorts 11, 12 , imply appreciably higher doses, some >1 Gy in certain bone marrow compartments, but a more detailed investigation of compartmental bone marrow doses would be needed to fully elucidate this. However, this heterogeneity would only matter if there was appreciable non-linearity in the leukaemia dose-response in this dose range, but we found no indication of this. The evidence is that if risks are being driven by anything in the non-LSS cohorts it is by the diagnostically-exposed groups, as is clear from Web-appendix p.23 -in general risks in the therapeutically-irradiated cohorts are less than those in diagnostically-exposed groups. Overall, the risk coefficients in the medically-exposed cohorts were, in general, slightly higher than, but statistically compatible with, those in the LSS (Web-appendix pp. [22] [23] , suggesting that the effect of any such non-linearity in dose response is slight.
The cohorts had a follow-up period extending over many years, in some groups from the early part of the last century. As a consequence, another limitation of this study is that disease coding may not be uniform even within a study or across countries. However, there was little evidence of this in aggregate -the variation in baseline risks between cohorts was modest, even where statistically significant (Web-appendix p. 26). In general, misclassification of a highly radiogenic outcome such as leukaemia would be expected to bias risk estimates towards the null, if non-differential with respect to exposure. Bias would not be expected if misclassification was only due to variations in sensitivity (e.g., for myelodysplastic syndromes, which were not diagnosed or reported during the early study periods). The relative risk models we used were stratified by cohort, and so a fortiori by country, and by calendar period, thus accounting for differences in baseline rates between countries, or over time, or both; however, more subtle variations in diagnosis would not have been captured by our modeling. The mixture of mortality and incidence data also complicates the interpretation because, inter alia, there was generally increasing treatment success over time, which was not uniform across endpoints; however, as we consider primarily relative risk models, and making the reasonable assumption that within a stratum (e.g., defined by cohort, calendar year, age, sex) a fixed proportion of the leukaemia cases would go on to die from that cause, independent of dose (i.e., the lethality does not depend on dose) one would not expect RR/100 mSv to differ appreciably in mortality compared with incidence. The relative risks were somewhat higher in the mortality cohorts than in the incidence cohorts, but the risks did not differ significantly in the two groups of cohorts (Web-appendix p.
24), therefore confirming the reasonableness of the relative risk model and these other assumptions.
It is perhaps notable that there is little evidence in the present study for departure from linearity (i.e., with excess risk proportional to dose) in the leukaemia dose-response (Webappendix p. 13), suggesting that over the dose range considered a linear dose response is appropriate. For this reason, we mostly modelled leukaemia risk using a simple linear relative risk model, a model that is commonly used in analysis of radio-epidemiological data 1 . The linearity is likely to be a reflection of the restriction of attention to the low-dose region (<100 mSv), in which dose-response curvature, based on what has been observed elsewhere (e.g., for acute myeloid leukaemia in the LSS 14 ) , would not be expected. The restriction of mean cumulative ABM doses to <100 mSv, and the consequent reduction in power of the main radiation effect, might reduce our ability to detect any modifying effects, so it is not particularly surprising that we found little evidence of an influence of time since exposure (Web-appendix pp. 14-15), age at exposure (Webappendix pp. [16] [17] or duration of exposure (Web-appendix p. 18).
There was, however, information on latency. The main analyses were conducted with an a priori chosen cumulative dose lag of 2 years, implicitly adopting the conventional assumption that the dose received within 2 years of leukaemia diagnosis/death does not affect risk 1 . A sensitivity analysis using dose lags of 0, 5 and 10 years showed that a minimum latent period of 2 years was broadly supported and that doses received 2-5 years before diagnosis/death were particularly influential, especially for acute lymphoblastic leukaemia (Web-appendix p. 20). There were also indications (p≈0.05) of excess acute myeloid leukaemia within 2 years of exposure (Web-appendix p. 19 ). This illustrates the importance of the eight medically-exposed cohorts in this study:
quantitative information on latency under 5 years cannot be derived from the LSS because the follow-up only commenced 5 years after the Japanese atomic bombings (although there was clear evidence of an earlier excess of leukaemia among the survivors before the establishment of the LSS cohort based on clinical reports 32 ).
With regard to limitations, the potential effects of selection and survival bias should also be considered. Neither the process by which we chose the nine cohorts for study nor the limitation within each cohort to those receiving doses <100 mSv should have introduced bias. The subjects in some cohorts had to survive until start of follow-up (e.g., Canadian TB, LSS, Swedish haemangioma), and in some instances to be eligible for inclusion they had existing medical conditions (e.g., TB, haemangioma, scoliosis) or suspected diseases (UK-NCI CT study). There has been concern about possible survival or selection bias in the LSS data, although the magnitude of any effect of such bias in relation to leukaemia appears to be modest 33 . There has also been concern about reverse causation and confounding by indication in the UK-NCI CT study, although for leukaemia with a 2-year dose lag there appears to be little evidence for the former 3 , and analysis excluding those with underlying medical conditions or pre-existing cancer had little effect on CTassociated leukaemia risk 34 . Adjustment for socioeconomic status hardly affected either leukaemia baseline risk or associated radiation risk in the UK-NCI CT study 3 , a finding paralleled in other radiation-exposed groups 25 . We collected a relatively limited set of variables for each cohort, so it is possible that confounding by some unmeasured factor could bias our results. However, the cohorts included in our analysis were characterised by few major known risk factors for leukaemia other than radiation 1, 35 , and thus, we posit that confounding is unlikely. The broad consistency of the findings across the different cohorts (Web-appendix pp. 21-23) also suggests that any shortcomings in the component cohorts, in particular biases and unmeasured confounding factors, did not impact materially on the findings of this study.
Dose error is also possible in all dose estimates that we used (Web-appendix pp. 2-3, 5).
There are two main types of dose error, classical dose error, which if unadjusted would be expected to bias results towards the null 36 , and Berkson error which would not be expected to introduce bias, although it might increase the variance of estimated trends with dose 36 . Therefore, in neither case would one expect such errors to introduce spurious trends with dose. In some cohorts, in particular the LSS, there has been validation of dosimetry via biological markers of exposure 18 .
The strengths of the present study are the prospective designs used in all component cohorts, individual ABM dose estimates, relative homogeneity of risk between cohorts (Web-appendix pp.
21-24, 26), as well as the generally long follow-up periods producing a large number of cases exposed at low doses.
There are radiobiological data supportive of a leukaemia risk following low dose exposure.
A number of studies have suggested an increase in stable chromosome aberrations and other markers of biological damage in peripheral blood lymphocytes (PBL) of nuclear workers and other groups with protracted radiation exposures, of a magnitude comparable with that seen in the LSS (reviewed in Little et al 37 ) . Such increases in chromosome aberrations have also been observed after very low dose irradiation of human PBL exposed ex vivo 38 . Furthermore, there is increasing evidence that chromosome changes play a major role in carcinogenesis, in particular leukaemia, reviewed elsewhere 39 , and that the presence of increased frequencies of chromosome aberrations in PBL in healthy individuals can be considered as surrogate markers for specific changes associated with carcinogenesis, and therefore be indicative of risk 39 . Indeed, fusion genes generated by chromosomal translocations have long been known to be consistent with genetic abnormalities in paediatric and some adult leukaemias 40 ; in particular the BCR-ABL translocation, which accounts for almost all cases of chronic myeloid leukaemia 40 .
In summary, we have documented radiogenic excess risks at mean cumulative ABM doses <100 mSv for acute myeloid leukaemia (with or without myelodysplastic syndromes) and acute lymphoblastic leukaemia. The relative risks are somewhat higher than, but compatible with, those seen in other studies with cumulative doses and dose rates both higher and lower than those studied here (Web-appendix p. 27). These findings suggest that there is risk of leukaemia associated with low-level exposure to radiation. As most exposures to workers and the general public stem from low doses 6 , the present study, among others, suggests that that the current system of radiological protection is prudent and not overly protective. The findings of the present study also add weight to efforts already underway (https://www.imagegently.org/) to minimise diagnostic radiological imaging, particularly in children, wherever possible. Continuing follow-up of these cohorts using up-to-date WHO disease classification combined with a comprehensive and consistent reevaluation of dosimetry will be valuable and informative.
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RESEARCH IN CONTEXT
Evidence before this study
Leukaemia has long been known to be among the most radiosensitive malignancies, and leukaemia generally appears sooner than any other cancer after radiation exposure. At moderate-to-high doses (>0.5 Sv) there is abundant evidence of radiation-related excess risk for most major leukaemia subtypes. Particularly high excess relative risks of leukaemia have been reported following radiation exposure in childhood. However, evidence of risk at lower doses is less well established, in particular at radiation doses of less than 100 mSv, the level of dose often used to demarcate low doses. We conducted PubMed searches at a number of points, and in final form on 29 th May 2018 using the terms "leukaemia" + "radiation" + "medical" + "diagnosis", "leukaemia" + "radiation" + "medical" + "therapy". We did not limit the language of publication. We also searched comprehensive overviews of the literature prepared by UNSCEAR (2008, 2013) and BEIR VII (2006) . We chose all available cohort studies reporting on or before 30 th June 2014 and with adequate dosimetry, with ≥5 leukaemias or myeloid malignancies receiving mean cumulative active bone marrow radiation doses >0.005 Sv while aged <21 years, but excluded any studies of patients being treated for malignant disease, in which chemotherapy is potentially a strong confounder.
Added value of this study
Although there have been previous pooled analyses of leukaemia, this study is the first to provide quantitative assessments of risk for exposures during childhood and adolescence of less than 100 mSv. In a pooled analysis of 9 cohorts with 262,573 subjects exposed at a young age to mean cumulative active bone marrow doses less than 100 mSv we demonstrated highly significant excess risks of acute myeloid leukaemia and acute lymphoblastic leukaemia. Excess risk was also observed for doses under 50 mSv for some endpoints. Exposures 2-5 years before diagnosis/death particularly influenced excess risk, with some indications of risk for exposures within 2 years of diagnosis. There were few indications of non-linearity in dose response, or inter-cohort heterogeneity, in particular between the medically-exposed groups and the Japanese atomic bomb survivors.
Implications of all the available evidence
The radiation risks in this study are somewhat higher than, but compatible with, those seen in other studies, with cumulative doses and dose rates both higher and lower than those studied here. The totality of these studies suggests that there is risk of leukaemia associated with low-level exposure to radiation. As most exposures to workers and the general public stem from low doses, the present study, among others, suggests that that the current system of radiological protection is prudent and not overly protective. The findings of the present study also add weight to efforts already underway (https://www.imagegently.org/) to minimise diagnostic radiological imaging, particularly in children, wherever possible.
